Mary C.  Beckerle net worth and biography

Mary Beckerle Biography and Net Worth

Director of Exelixis

Mary C. Beckerle, Ph.D., has been a director since January 2024. Since 2006, Dr. Beckerle has served as Chief Executive Officer of the Huntsman Cancer Institute at the University of Utah, and is also currently serving as Associate Vice President for Cancer Affairs and a Distinguished Professor of Biology and Oncological Sciences at the University of Utah. She first joined the faculty of the University of Utah in 1986, serving in numerous research and leadership positions over the years, and currently holds the Jon M. Huntsman Presidential Endowed Chair. Dr. Beckerle has served as a member of the board of directors of Huntsman Corporation, a publicly held global manufacturer of specialty chemicals, since 2011, and as a member of the board of directors of Johnson & Johnson, a publicly held diversified healthcare company, since 2015. She has been named a National Association of Corporate Directors (NACD) Corporate Governance Fellow and was a 2018 NACD Directorship 100 Honoree. In addition, she currently serves on a number of scientific and other advisory boards, including the Medical Advisory Board of the Howard Hughes Medical Institute since 2015, as well as on various external advisory boards of National Cancer Institute-designated cancer centers. Previously, Dr. Beckerle served as a member of the Board of Scientific Advisors of the National Cancer Institute from 2018 to 2022, the External Advisory Board of the Dana-Farber/Harvard Cancer Center from 2013 to 2022, the Board of Directors of the American Association for Cancer Research from 2013 to 2016, the American Cancer Society Council for Extramural Grants from 2008 to 2012 (serving as Chair from 2010 to 2012) and the National Institute of Health’s Advisory Committee to the Director from 2007 to 2010, as well as President of the American Society for Cell Biology from 2006 to 2007. She is also an elected member of the National Academy of Sciences, the American Philosophical Society and the American Academy of Arts and Sciences. Dr. Beckerle holds a B.A. in Biology and Psychology (magna cum laude) from Wells College and a Ph.D. in Molecular, Cellular and Developmental Biology from the University of Colorado, Boulder. She completed her post-doctoral fellowship in Anatomy and Cell Biology at the University of North Carolina at Chapel Hill.

What is Mary C. Beckerle's net worth?

The estimated net worth of Mary C. Beckerle is at least $1.13 million as of February 14th, 2025. Beckerle owns 30,406 shares of Exelixis stock worth more than $1,126,694 as of March 26th. This net worth evaluation does not reflect any other investments that Beckerle may own. Learn More about Mary C. Beckerle's net worth.

How do I contact Mary C. Beckerle?

The corporate mailing address for Beckerle and other Exelixis executives is 1851 Harbor Bay Parkway, Alameda CA, 94502. Exelixis can also be reached via phone at (650) 837-7000 and via email at shubbard@exelixis.com. Learn More on Mary C. Beckerle's contact information.

Has Mary C. Beckerle been buying or selling shares of Exelixis?

In the last ninety days, Mary C. Beckerle has sold $425,884.80 in Exelixis stock. Most recently, Mary C. Beckerle sold 12,210 shares of the business's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $34.88, for a transaction totalling $425,884.80. Following the completion of the sale, the director now directly owns 30,406 shares of the company's stock, valued at $1,060,561.28. Learn More on Mary C. Beckerle's trading history.

Who are Exelixis' active insiders?

Exelixis' insider roster includes Dana Aftab (EVP), Mary Beckerle (Director), Charles Cohen (Director), Carl Feldbaum (Director), Maria Freire (Director), Maria Freire (Director), Alan Garber (Director), Patrick Haley (EVP), Jeffrey Hessekiel (EVP), David Johnson (Director), Peter Lamb (EVP), Vincent Marchesi (Director), Michael Morrissey (CEO), Bob Oliver (Director), Stelios Papadopoulos (Director), George Poste (Director), Gisela Schwab (CMO), Christopher Senner (CFO), Lance Willsey (Director), and Jack Wyszomierski (Director). Learn More on Exelixis' active insiders.

Are insiders buying or selling shares of Exelixis?

In the last year, Exelixis insiders bought shares 2 times. They purchased a total of 425,000 shares worth more than $8,735,000.00. In the last year, insiders at the biotechnology company sold shares 25 times. They sold a total of 813,833 shares worth more than $25,327,150.37. The most recent insider tranaction occured on March, 3rd when EVP Patrick J Haley sold 10,000 shares worth more than $388,000.00. Insiders at Exelixis own 2.9% of the company. Learn More about insider trades at Exelixis.

Information on this page was last updated on 3/3/2025.

Mary C. Beckerle Insider Trading History at Exelixis

See Full Table

Mary C. Beckerle Buying and Selling Activity at Exelixis

This chart shows Mary C Beckerle's buying and selling at Exelixis by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$426ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$400k-$200k$0$200k$400kTotal Insider BuyingTotal Insider Selling

Exelixis Company Overview

Exelixis logo
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Read More

Today's Range

Now: $37.01
Low: $36.71
High: $38.41

50 Day Range

MA: $35.69
Low: $32.38
High: $39.15

2 Week Range

Now: $37.01
Low: $20.14
High: $40.02

Volume

2,448,035 shs

Average Volume

2,091,196 shs

Market Capitalization

$10.36 billion

P/E Ratio

20.91

Dividend Yield

N/A

Beta

0.57